COMMUNIQUÉS West-GlobeNewswire

ITM to Present at the 43rd Annual J.P. Morgan Healthcare Conference

13/12/2024 - 11:00

Garching / Munich, Germany, December 13, 2024 – ITM Isotope Technologies Munich SE (ITM), a leading radiopharmaceutical biotech company, today announced that its Chief Executive Officer, Dr. Andrew Cavey and Chief [...]

La formulation sous-cutanée de DARZALEX® (daratumumab) démontre une réduction de 51 pour cent du risque de progression vers un myélome multiple actif chez des patients atteints d’un myélome multiple indolent à haut risque

13/12/2024 - 11:38

Le premier traitement sous-cutané anti-CD38 à démontrer un potentiel de prévention des lésions au niveau des organes cibles et de prolongation de la survie sans progression et de la survie globale, d’après les résultats [...]

‘A Tragedy in the Making’: Approval of Canada’s Proposed $32.5 Billion Big Tobacco Settlement Risks Leaving Millions Living with Lung Disease Behind, Warns National Lung Health Alliance (NLHA)

13/12/2024 - 11:50

Leading patient advocacy network urges provinces to use settlement pay-outs solely to combat lung disease following historic creditors vote on December 12 TORONTO, Dec. 13, 2024 (GLOBE NEWSWIRE) -- The National Lung [...]

The Ensign Group, Inc. Increases Quarterly Dividend to $0.0625 Per Share

13/12/2024 - 12:00

SAN JUAN CAPISTRANO, Calif., Dec. 13, 2024 (GLOBE NEWSWIRE) -- The Ensign Group, Inc. (Nasdaq: ENSG), the parent company of the Ensign™ group of companies, which invest in and provide skilled nursing and senior living [...]

Polyrizon Announces Appointment of VP of Regulatory Affairs and Quality Assurance

13/12/2024 - 12:25

Raanana, Israel, Dec. 13, 2024 (GLOBE NEWSWIRE) -- Polyrizon Ltd. (Nasdaq: PLRZ) (the "Company" or "Polyrizon"), a development stage biotech company specializing in the development of innovative intranasal hydrogels, [...]

Monte Rosa Therapeutics Appoints Dr. Eric A. Hughes to Board of Directors

13/12/2024 - 13:00

BOSTON, Dec. 13, 2024 (GLOBE NEWSWIRE) -- Monte Rosa Therapeutics, Inc. (Nasdaq: GLUE), a clinical-stage biotechnology company developing novel molecular glue degrader (MGD)-based medicines, today announced the [...]

Ocular Therapeutix™ Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

13/12/2024 - 13:00

BEDFORD, Mass., Dec. 13, 2024 (GLOBE NEWSWIRE) -- Ocular Therapeutix, Inc. (NASDAQ:OCUL, “Ocular”), a biopharmaceutical company committed to improving vision in the real world through the development and [...]

Genelux Corporation to Participate in a Fireside Chat with H.C. Wainwright

13/12/2024 - 13:01

WESTLAKE VILLAGE, Calif., Dec. 13, 2024 (GLOBE NEWSWIRE) -- Genelux Corporation (NASDAQ: GNLX), a late clinical-stage immuno-oncology company, today announced that Thomas Zindrick , President, CEO and Chairman of the [...]

Roche’s Vabysmo prefilled syringe (PFS) approved in the EU for three retinal conditions that can cause blindness

13/12/2024 - 07:10

Vabysmo PFS is the first and only prefilled syringe containing a bispecific antibody, offering a convenient alternative to currently available Vabysmo vials Vabysmo has demonstrated rapid and robust vision and [...]

New Incentive Program Established for Members of Executive Management and Selected Employees in Bavarian Nordic

13/12/2024 - 08:00

COPENHAGEN, Denmark, December 13, 2024 – Bavarian Nordic A/S (OMX: BAVA) announced today that the Board of Directors has decided to establish a new long-term incentive program for Executive Management and selected [...]

Nyxoah Annonce le Lancement Commercial de la Thérapie Innovante Genio® en Angleterre

13/12/2024 - 08:05

Nyxoah Annonce le Lancement Commercial de la Thérapie Innovante Genio® en Angleterre Premiers patients implantés avec Genio à l'UCLH, Londres Mont-Saint-Guibert, Belgique – 13 Décembre 2024, 8h05 CET / 2h05 ET – Nyxoah [...]

Nyxoah Announces Commercial Launch of Genio® Innovative Therapy in England

13/12/2024 - 08:05

Nyxoah Announces Commercial Launch of Genio® Innovative Therapy in England First patients implanted with Genio at UCLH, London Mont-Saint-Guibert, Belgium – December 13, 2024, 8:05am CET / 2:05am ET – Nyxoah SA ( [...]

Actimed Therapeutics Announces Publication of Successful S-pindolol benzoate (ACM-001.1) Phase 1 Study in The Journal of Cachexia, Sarcopenia and Muscle

13/12/2024 - 09:00

London, UK – 13 th December 2024. Actimed Therapeutics Ltd (“Actimed”), a UK based clinical stage speciality pharmaceutical company focused on bringing innovation to the treatment of cancer cachexia and other muscle [...]

Candel Therapeutics Announces Pricing of Public Offering

13/12/2024 - 05:00

NEEDHAM, Mass., Dec. 12, 2024 (GLOBE NEWSWIRE) -- Candel Therapeutics, Inc. (“Candel”) (Nasdaq: CADL), a clinical stage biopharmaceutical company focused on developing multimodal biological immunotherapies to help [...]

Roche receives CE Mark for new and updated molecular cobas 6800/8800 systems, enhancing laboratory efficiency and testing capabilities

13/12/2024 - 07:00

The new cobas 6800/8800 systems 2.0 enhances throughput, run flexibility, enables sample prioritisation and is available as an upgrade to existing systems in healthcare settings around the world. Laboratories can now [...]

Communiqué de presse : Le tolebrutinib obtient la désignation de « Médicament innovant » de la FDA pour le traitement de la sclérose en plaques secondairement progressive sans poussées

13/12/2024 - 07:00

Le tolebrutinib obtient la désignation de « Médicament innovant » de la FDA pour le traitement de la sclérose en plaques secondairement progressive sans poussées Désignation motivée par les résultats positifs de l’étude [...]

Press Release: Tolebrutinib designated Breakthrough Therapy by the FDA for non-relapsing secondary progressive multiple sclerosis

13/12/2024 - 07:00

Tolebrutinib designated Breakthrough Therapy by the FDA for non-relapsing secondary progressive multiple sclerosis Designation is based on positive results from the HERCULES study in adults with non-relapsing secondary [...]

HUTCHMED to Receive Milestone Payment from Takeda following First European Reimbursement for FRUZAQLA® (fruquintinib)

13/12/2024 - 01:00

— US$10 million milestone payment to HUTCHMED follows first national reimbursement in Europe — — Follows June 2024 European approval of FRUZAQLA ® (fruquintinib), the first novel oral targeted therapy in the EU for [...]

LakeShore Biopharma Provides Update on Ongoing Criminal Investigation Involving Former Chairman in China

13/12/2024 - 01:57

BEIJING, Dec. 12, 2024 (GLOBE NEWSWIRE) -- LakeShore Biopharma Co., Ltd. (Nasdaq: LSB) (“LakeShore Biopharma” or the “Company”), a leading global biopharmaceutical company focused on the innovation and production of [...]